Loading...

Douglas Drake (ChemAxon): ChemAxon Science

28 views

Loading...

Loading...

Transcript

The interactive transcript could not be loaded.

Loading...

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Jul 16, 2013

In 2012, 26 of the 39 new therapeutic products approved by the FDA, two thirds of the total, were small molecule drugs indicating that medicinal chemistry is still the forefront of drug discovery R&D. Despite this, drug discovery chemistry is a multi-tiered problem: from identifying a therapeutic MOA, to making unique and defensible chemistry, to SAR and pharmacophore modeling, to understanding pharmacokinetic properties, bioavailability and safety. Each aspect builds on the rest because it is not just about making a unique and therapeutically active compound; it is also about being able to deliver it effectively and safely within patients. The following presentations highlight various aspects of how ChemAxon's products and tools can be used in drug discovery chemistry; from reaction mapping, property calculation, structure filtering and virtual screening to metabolite prediction, chemistry text analytics and knowledge management and as well as our recent advances in biomolecular structure management.

Loading...

When autoplay is enabled, a suggested video will automatically play next.

Up next


to add this to Watch Later

Add to

Loading playlists...